The in vitro pharmacological profile of TD-1211, a neutral opioid receptor antagonist

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 386, Issue 6, 2013, Pages 479-491

  Tsuruda, Pamela R ^a   Vickery, Ross G ^a   Long, Daniel D ^a   Armstrong, Scott R ^a   Beattie, David T ^a  

^a THERAVANCE INC   (United States)

Author keywords

Alvimopan; Constipation; Methylnaltrexone; Opioid receptor; TD 1211

Indexed keywords

17 METHYLNALTREXONE; ALVIMOPAN; DELTA OPIATE RECEPTOR; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; KAPPA OPIATE RECEPTOR; LOPERAMIDE; MORPHINE; MU OPIATE RECEPTOR; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; NALTREXONE; OPIATE ANTAGONIST; TD 1211; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; CONSTIPATION; CONTROLLED STUDY; DISSOCIATION CONSTANT; DRUG EFFICACY; EVOKED RESPONSE; EX VIVO STUDY; GUINEA PIG; ILEUM; IN VITRO STUDY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN TARGETING; STRUCTURE ACTIVITY RELATION;

ANIMALS; BENZAMIDES; CHO CELLS; CRICETINAE; CRICETULUS; GUINEA PIGS; HUMANS; MALE; MESOCRICETUS; NALTREXONE; NARCOTIC ANTAGONISTS; PIPERIDINES; QUATERNARY AMMONIUM COMPOUNDS; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU; TROPANES;

EID: 84878020398     PISSN: 00281298     EISSN: 14321912     Source Type: Journal    
DOI: 10.1007/s00210-013-0850-7     Document Type: Article

References (54)

1. Armstrong SR, Campbell CB, Richardson CL, Vickery RG, Tsuruda PR, Long DD, Hegde SS, Beattie DT (2013) The in vivo pharmacology of TD-1211, a peripherally-selective opioid receptor antagonist in development for the treatment of opioid-induced constipation. Naunyn-Schmiedeberg's Arch Pharm. doi: 10.1007/s00210-013-0844-5
2. Arunlakshana O, Schild HO (1959) Some quantitative uses of drug antagonists. Br J Pharmacol Chemotherap 14:48-58
3. Beattie DT, Cheruvu M, Mai N, O'Keefe M, Johnson-Rabidoux S, Peterson C, Kaufman E, Vickery R (2007) The in vitro pharmacology of the peripherally restricted opioid receptor antagonists, alvimopan, ADL 08-0011 and methylnaltrexone. Naunyn Schmiedeberg's Arch Pharmacol 375:205-220
4. Brent PJ, Chahl LA, Cantarella PA, Kavanagh C (1993) The kappa-opioid receptor agonist U50,488H induces acute physical dependence in guinea-pigs. Eur J Pharmacol 241:149-156
5. Brock C, Olesen SS, Olesen AE, Frokjaer JB, Andresen T, Drewes AM (2012) Opioid-induced bowel dysfunction. Drugs 72:1847-1865
6. Calderon SN, Rothman RB, Porreca F, Flippen-Anderson JL, McNutt RW, Xu H, Smith LE, Bilsky EJ, Davis P, Rice KC (1994) Probes for narcotic receptor mediated phenomena. 19. Synthesis of (+)-4-[(alpha R)-alpha-((2S,5R)-4-allyl-2, 5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide (SNC 80): a highly selective, nonpeptide delta opioid receptor agonist. J Med Chem 37:2125-3128
7. Cassel JA, Daubert JD, DeHaven RN (2005) [(3)H]Alvimopan binding to the micro opioid receptor: comparative binding kinetics of opioid antagonists. Eur J Pharmacol 520:29-36
8. 50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108
9. Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, Davies P, Donovan MI, Fishbain DA, Foley KM, Fudin J, Gilson AM, Kelter A, Mauskop A, O'Connor PG, Passik SD, Pasternak GW, Portenoy RK, Rich BA, Roberts RG, Todd KH, Miaskowski C (2009) Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 10:113-130
10. Collier HOJ, Cuthbert NJ, Francis DL (1981) Model of opiate dependence in the guinea-pig isolated ileum. Br J Pharmacol 73:921-932
11. Culpepper-Morgan JA, Holt PR, LaRoche D, Kreek MJ (1995) Orally administered opioid antagonists reverse both mu and kappa opioid agonist delay of gastrointestinal transit in the guinea pig. Life Sci 56:1187-1192
12. Culpepper-Morgan JA, Inurrisi CE, Portenoy RK, Foley K, Houde RW, Marsh F, Kreek MJ (1992) Treatment of opioid-induced constipation with oral naloxone: a pilot study. Clin Pharmacol Therap 52:90-95
13. Deibert P, Xander C, Blum HE, Becker G (2010) Methylnaltrexone: the evidence for its use in the management of opioid-induced constipation. Core Evid 4:247-258
14. De Luca A, Coupar IM (1996) Insights into opioid action in the intestinal tract. Pharmacol Ther 69:103-115
15. Johnson SM, Williams JT, Costa M, Furness JB (1987) Naloxone-induced depolarization and synaptic activation of myenteric neurons in morphine-dependent guinea pig ileum. Neurosci 21:595-602
16. Kapitzke D, Vetter I, Cabot PJ (2005) Endogenous opioid analgesia in peripheral tissues and the clinical implications for pain control. Ther Clin Risk Manag 1(4):279-297
17. Kojima Y, Takahashi T, Fujina M, Owyang C (1994) Inhibition of cholinergic transmission by opiates in ileal myenteric plexus is mediated by kappa receptor. Involvement of regulatory inhibitory G protein and calcium N-channels. J Pharmacol Exp Therap 268:965-970
18. Kosterlitz HW, Watt AJ (1968) Kinetic parameters of narcotic agonists and antagonists, with particular reference to N-allylnoroxymorphone (naloxone). Br J Pharmacol 33:266-277
19. Kraft M, Maclaren R, Du W, Owens G (2010) Alvimopan (entereg) for the management of postoperative ileus in patients undergoing bowel resection. Pharm Therap 35:44-49
20. Kromer W, Steigemann N, Shearman GT (1982) Differential effects of SKF 10,047 (N-allyl-normetazocine) on peristalsis and longitudinal muscle contractions of the isolated guinea-pig ileum. Naunyn-Schmiedeberg's Arch Pharmacol 321:218-222
21. Kurz A, Sessler DI (2003) Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs 63:649-671
22. Lagrutta AA, Trepakova ES, Salata JJ (2008) The hERG channel and risk of dug-acquired cardiac arrhythmia: an overview. Curr Topics Med Chem 8:1102-1112
23. Lazorthes YR, Sallerin BA-M, Verdie J-CP (1995) Intracerebroventricular administration of morphine for control of irreducible cancer pain. Neurosurg 37:422-428
24. Lucero M, Von Scheele B, Blackard R, Milanova T, Bell T (2006) Amer Pain Soc Meeting, poster #959.
25. Lujan M, Rodriguez R (1981) Pharmacological characterization of opiate physical dependence in the isolated ileum of the guinea-pig. Br J Pharmacol 73:859-866
26. Mako E, Ronai AZ, Adam G, Juhasz G, Ritter L, Lestar B, Crunelli V (2000) Modulation by GABA(B) and delta opioid receptors of neurally induced responses in isolated guinea-pig taenia coli and human colonic circular muscle. J Physiol Paris 94:135-138
27. McKnight AT, Corbett AD, Marcoli M, Kosterlitz HW (1985) The opioid receptors in the hamster vas deferens are of the delta-type. Neuropharmacol 24:1011-1017
28. Meissner W, Schmidt U, Hartmann M, Kath R, Reinhart K (2000) Oral naloxone reverses opioid-associated constipation. Pain 84:105-109
29. Mercadante S (1999) Problems of long-term spinal opioid treatment in advanced cancer patients. Pain 79:1-13
30. Nakayama S, Taniyama K, Matsuyama S, Ohgushi N, Tsunekawa K, Tanaka C (1990) Regulatory role of enteric mu and kappa opioid receptors in the release of acetylcholine and norepinephrine from guinea pig ileum. J Pharmacol Exp Therap 254:792-798
31. Nishiwaki H, Saitoh N, Nishio H, Takeuchi T, Hata F (1998a) Inhibitory effect of endomorphin-1 and -2 on acetylcholine release from myenteric plexus of guinea pig ileum. Jap J Pharmacol 78:83-86
32. Nishiwaki H, Saitoh N, Nishio H, Takeuchi T, Hata F (1998b) Relationship between inhibitory effect of endogenous opioid via mu-receptors and muscarinic autoinhibition in acetylcholine release from myenteric plexus of guinea pig ileum. Jap J Pharmacol 77:279-286
33. Pappagallo M (2001) Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surgery 182:11S-18S
34. Pol O, Ferrer I, Puig MM (1994) Diarrhea associated with intestinal inflammation increases the potency of mu and delta opioids on the inhibition of gastrointestinal transit in mice. J Pharmacol Exp Ther 270(1):386-391
35. Porreca F, Galligan JJ, Burks TF (1986) Central opioid receptor involvement in gastrointestinal motility. Trends Pharmacol Sci 7:104-107
36. Sadée W, Wang D, Bilsky EJ (2005) Basal opioid receptor activity, neutral antagonists, and therapeutic opportunities. Life Sci 76:1427-1437
37. Seiwald M, Alesch F, Kofler A (1996) Intraventricular morphine administration as a treatment possibility for patients with intractable pain. Wien Klin Wochenschr 108:5-8
38. + channels. Mol Pharmacol 69:921-931
39. Smith JAM, Beattie DT, Marquess D, Shaw J-P, Vickery RG, Humphrey PPA (2008) The in vitro pharmacological profile of TD-5108, a selective 5-HT4 receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch Pharmacol 378:125-137
40. Sternini C, Patierno S, Selmer IS, Kirchgessner A (2004) The opioid system in the gastrointestinal tract. Neurogastroenterol Motil 16(suppl 2):3-16
41. Valeri P, Morrone LA, Romanelli L, Amico MC (1995) Acute withdrawal after bremazocine and the interaction between mu- and kappa-opioid receptors in isolated gut tissues. Br J Pharmacol 114:1206-1210
42. Vanegas G, Ripamonti C, Sbanotto A, De Conno F (1998) Side effects of morphine administration in cancer patients. Cancer Nursing 21:289-297
43. Vickery R, Li Y-P, Schwertschlag U, Singla N, Webster L, Canafax D (2012) TD-1211 demonstrates improvement in bowel movement frequency without impacting analgesia in a Phase 2b study of patients with opioid-induced constipation. Pain Week, Las Vegas, NV, September 5-8. Poster #121. http://www.painweek.org/ scientificposters/2012-accepted-abstracts
44. Viscusi ER, Gan TJ, Leslie JB, Foss JF, Talon MD, Du W, Owens G (2009) Peripherally acting mu-opioid receptor antagonists and postoperative ileus: mechanisms of action and clinical applicability. Anaesth Analg 108:1811-1822
45. Wade PR, Palmer JM, McKenney S, Kenigs V, Chevalier K, Moore BA, Mabus JR, Saunders PR, Wallace NH, Schneider CR, Kimball ES, Breslin HJ, He W, Hornby PJ (2012) Modulation of gastrointestinal function by MuDelta, a mixed μ opioid receptor agonist/μ opioid receptor antagonist. Br J Pharmacol 167(5):1111-1125
46. Walsh TD (1990) Prevention of opioid side effects. J Pain Symptom Manag 5:362-367
47. Walsh TD (2000) Pharmacological management of cancer pain. Seminars in Oncology 27:45-63
48. Walters JB, Montagnini M (2010) Current concepts in the management of opioid-induced constipation. J Opioid Management 66:435-444
49. Wang D, Bilsky EJ, Porreca F, Sadée W (1994) Constitutive mu opioid receptor activation as a regulatory mechanism underlying narcotic tolerance and dependence. Life Sci 54:339-350
50. Wang D, Raehal KM, Bilsky EJ, Sadée W (2001) Inverse agonists and neutral antagonists at mu opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence. J Neurochem 77:1590-1600
51. Wang D, Sun X, Sadée W (2007) Different effects of opioid antagonists on mu-, delta-, and kappa-opioid receptors with and without agonist pretreatment. J Pharmacol Exp Therap 321:544-552
52. Wood JD, Galligan JJ (2004) Function of opioids in the enteric nervous system. Neurogastroenterol Motil 16(suppl 2):17-28
53. Yassen A, Olofsen E, Dahan A, Danhof M (2005) Pharmacokinetic- pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: role of receptor equilibration kinetics. J Pharmacol Exp Ther 313:1136-1149
54. Zagorodnyuk V, Maggi CA (1994) Electrophysiological evidence for different release mechanism of ATP and NO as inhibitory NANC transmitters in guinea-pig colon. Br J Pharmacol 112:1077-1082